Antiproliferative action of metformin in human lung cancer cell lines

Oncology Reports

Volumn 28, Issue 1, 2012, Pages 8-14

  Ashinuma, Hironori ^a   Takiguchi, Yuichi ^a   Kitazono, Satoru ^a   Kitazono Saitoh, Miyako ^a   Kitamura, Atsushi ^a   Chiba, Tetsuhiro ^a   Tada, Yuji ^a   Kurosu, Katsushi ^a   Sakaida, Emiko ^a   Sekine, Ikuo ^a   Tanabe, Nobuhiro ^a   Iwama, Atsushi ^a   Yokosuka, Osamu ^a   Tatsumi, Koichiro ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cell cycle; Cell line; Cisplatin; Lung cancer; Metformin

Indexed keywords

CASPASE; CISPLATIN; METFORMIN;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CLONOGENESIS; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG INHIBITION; ENZYME ACTIVATION; FIBROBLAST; HISTOLOGY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MESOTHELIUM CELL; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; BALB 3T3 CELLS; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG INTERACTIONS; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; METFORMIN; MICE;

EID: 84861540166     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1763     Document Type: Article

References (22)

1. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305, 2005. (Pubitemid 40813563)
2. Bowker SL, Majumdar SR, Veugelers P and Johnson JA: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254-258, 2006. (Pubitemid 44106500)
3. Jiralerspong S, Palla SL, Giordano SH, et al: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27: 3297-3302, 2009.
4. Mazzone PJ, Rai HS, Beukemann M, Xu M, Abdallah R and Sasidhar M: The effect of metformin and thiazolidinedione use on lung cancer. Chest 138: 882A, 2010.
5. Alimova IN, Liu B, Fan Z, et al: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8: 909-915, 2009.
6. Liu B, Fan Z, Edgerton SM, et al: Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8: 2031-2040, 2009.
7. Zakikhani M, Dowling R, Fantus IG, Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269-10273, 2006. (Pubitemid 44799743)
8. Rocha GZ, Dias MM, Ropelle ER, et al: Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res 17: 3993-4005, 2011.
9. Ben Sahra I, Laurent K, Loubat A, et al: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27: 3576-3586, 2008. (Pubitemid 351793803)
10. Wang LW, Li ZS, Zou DW, Jin ZD, Gao J and Xu GM: Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol 14: 7192-7198, 2008.
11. Gotlieb WH, Saumet J, Beauchamp MC, et al: In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 110: 246-250, 2008.
12. Rattan R, Giri S, Hartmann LC and Shridhar V: Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 15: 166-178, 2011.
13. Rattan R, Graham RP, Maguire JL, Giri S and Shridhar V: Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 13: 483-491, 2011.
14. Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928, 2008.
15. Goodwin PJ, Ligibel JA and Stambolic V: Metformin in breast cancer: time for action. J Clin Oncol 27: 3271-3273, 2009.
16. Algire C, Zakikhani M, Blouin MJ, Shuai JH and Pollak M: Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer 15: 833-839, 2008.
17. Iliopoulos D, Hirsch HA and Struhl K: Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Research 71: 3196-3201, 2011.
18. Janjetovic K, Vucicevic L, Misirkic M, et al: Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur J Pharmacol 651: 41-50, 2011.
19. Harhaji-Trajkovic L, Vilimanovich U, Kravic-Stevovic T, Bumbasirevic V and Trajkovic V: AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells. J Cell Mol Med 13: 3644-3654, 2009.
20. Sugimoto T, Takiguchi Y, Kurosu K, et al: Growth factor-mediated interaction between tumor cells and stromal fibroblasts in an experimental model of human small-cell lung cancer. Oncol Rep 14: 823-830, 2005.
21. Iwase M, Nohara S, Sasaki N, et al: Pharmacokinetics study of low dose of metformin clinically used in Japan. J Japan Diab Soc 47: 197-201, 2004. (Pubitemid 38590795)
22. Wilcock C and Bailey CJ: Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 24: 49-57, 1994. (Pubitemid 24058005)